<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73708">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700543</url>
  </required_header>
  <id_info>
    <org_study_id>CME2012-01E</org_study_id>
    <secondary_id>1201E</secondary_id>
    <nct_id>NCT01700543</nct_id>
  </id_info>
  <brief_title>Sidus(TM) Post Market Clinical Follow-up (PMCF) Study</brief_title>
  <official_title>Sidus(TM) Stem-Free Shoulder - A Multi-center, Prospective, Non-controlled Post Market Clinical Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zimmer, GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zimmer, Inc.</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post market clinical follow-up study is designed to confirm safety and performance of
      the Sidus Stem-Free Shoulder when used in hemi or total shoulder arthroplasty.

      The safety of the implant will be evaluated by monitoring the frequency and incidence of all
      kinds of adverse events.

      The performance will be determined by analyzing the implant survival, overall pain and
      functional performances (based on Constant &amp; Murley score and ASES score), subject quality
      of life (EuroQol EQ5D) and radiographic parameters (e.g. radiolucencies, osteolysis,
      component migration) of study subjects who received the Sidus Stem-Free Shoulder.

      The Sidus Stem-Free Shoulder is not approved for use in the US.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, noncontrolled, multi-center post market clinical follow-up
      study involving orthopedic surgeons skilled in hemi and total shoulder arthroplasty
      procedures.

      A total number of 160 subjects will be included in the study.

      Ethics Committee (EC) approval for each site has to be obtained prior to conducting this
      study.  Sequentially, all eligible patients will be offered study enrollment at each center
      to avoid potential selection bias.  All potential subjects will be required to participate
      in an informed consent process and sign the EC approved written Informed Consent prior to
      study enrollment.

      The study is designed to be prospective to ensure that the study population is
      representative of the type of population that the device is intended to treat.  Patients
      will be selected according to the subject selection criteria described in section 8.  All
      subjects will undergo preoperative, intraoperative and immediate postoperative assessments
      including physical examinations, radiographic evaluations and collection of quality of life
      metrics.  Follow-up evaluations are to be conducted at 3 and 6 months, 1, 2, 5, 7 and 10
      years postoperation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Functional Performance (Constant &amp; Murley Score)</measure>
    <time_frame>5 Years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival (Kaplan-Meier)</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-inflammatory Degenerative Joint Disease (NIDJD)</condition>
  <condition>Avascular Necrosis</condition>
  <condition>Osteoarthritis</condition>
  <condition>Inflammatory Joint Disease (IJD)</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Shoulder Arthroplasty</intervention_name>
    <description>Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>HSA</other_name>
    <other_name>TSA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients indicated for hemi or total shoulder arthroplasty with good bone stock who
        fulfill all inclusion and none of the exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 to 80 years of age, inclusive.

          -  The patient is skeletally mature.

          -  Patient is suffering from severe shoulder pain and disability requiring unilateral or
             bilateral HSA or TSA based on physical exam and medical history.

          -  Patient has failed conservative treatment.

          -  Patient meets at least one of the following indications:  Osteoarthritis,
             Posttraumatic arthrosis, Rheumatoid arthritis without humeral metaphyseal defects,
             Focal avascular necrosis of the humeral head, Previous surgeries of the shoulder that
             do no compromise the fixation.

          -  Patient is willing and able to cooperate in the required post-operative therapy.

          -  Patient is willing and able to complete scheduled follow-up evaluations as described
             in the Informed Consent.

          -  Patient has participated in the Informed Consent process and has signed the Ethics
             Committee approved &quot;Informed Consent&quot;.

        Exclusion Criteria:

          -  Patient is unwilling or unable to give consent or to comply with the follow-up
             program.

          -  Patients who have any condition which would in the judgement of the Investigator
             place the patient at undue risk or interfere with the study.  Any patient who is
             institutionalized, or is an known drug abuser, a known alcoholic or anyone who cannot
             understand what is required of them.

          -  Patient is known to be pregnant or breastfeeding.

          -  Patient meets at least one of the contraindications:  Soft or inadequate humeral bone
             (including osteoporosis and extensive avascular necrosis or rheumatoid arthritis)
             leading to poor implant fixation, Metaphyseal bony defect (including large cysts),
             Posttraumatic tuberosity non-union, Signs of infection, Irreparable cuff tear,
             Revision from a failed stemmed prosthesis, Charcot's shoulder (neuroarthropathy)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Poulios, Dr</last_name>
      <email>nikos.poulios@akh.linz.at</email>
    </contact>
    <investigator>
      <last_name>Nikolaus Boehler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Chirurgical Thiers</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bellon-Champel, Dr</last_name>
      <email>p.bellonchampel@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Bellon-Champel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Mansat, Prof</last_name>
      <email>mansat.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Mansat, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charit√©</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Scheibel, Prof</last_name>
      <email>markus.scheibel@charite.de</email>
    </contact>
    <investigator>
      <last_name>Markus Scheibel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopaedische Chirurgie Muenchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernst Wiedemann, Prof</last_name>
      <email>ocm@ocm-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Ernst Wiedemann, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis am Wall</name>
      <address>
        <city>Rinteln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bartsch, Dr</last_name>
      <email>info@paw-rinteln.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Bartsch, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renzo Angeloni, Dr</last_name>
      <phone>+390557947111</phone>
    </contact>
    <investigator>
      <last_name>Renzo Angeloni, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen</name>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Jost, Prof</last_name>
      <email>bernhard.jost@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Bernhard Jost, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie McBirnie</last_name>
      <email>julie.mcbirnie@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Julie McBirnie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stemless shoulder implant</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Hemi Shoulder Arthroplasty</keyword>
  <keyword>Total Shoulder Arthroplasty</keyword>
  <keyword>Prospective</keyword>
  <keyword>Multi-center</keyword>
  <keyword>Europe</keyword>
  <keyword>Non-Controlled</keyword>
  <keyword>Good Bone Stock</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
